Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

natera inc - NTRA

NTRA

Close Chg Chg %
194.52 2.85 1.47%

Closed Market

197.37

+2.85 (1.47%)

Volume: 665.31K

Last Updated:

Mar 25, 2026, 4:00 PM EDT

Trade Now

Company Overview: natera inc - NTRA

NTRA Key Data

Open

$196.83

 Day Range

195.79 - 202.88

52 Week Range

125.38 - 256.27

 Market Cap

$27.57B

Shares Outstanding

141.73M

 Public Float

134.84M

Beta

1.64

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.54

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.39M

  

NTRA Performance

1 Week
 
 1.07%
 
1 Month
 
 -5.13%
 
3 Months
 
 -15.56%
 
1 Year
 
 37.12%
 
5 Years
 
 110.78%
 

NTRA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About natera inc - NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

NTRA At a Glance

Natera, Inc.
Building A, 13011 McCallen Pass
Austin, Texas 78753
Phone 1-650-980-9190 Revenue 2.31B
Industry Biotechnology Net Income -208,160,000.00
Sector Health Technology 2025 Sales Growth 35.901%
Fiscal Year-end 12 / 2026 Employees 6,140
View SEC Filings

NTRA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 13.582
Price to Book Ratio 18.688
Price to Cash Flow Ratio 145.48
Enterprise Value to EBITDA -116.025
Enterprise Value to Sales 13.208
Total Debt to Enterprise Value 0.007

NTRA Efficiency

Revenue/Employee 375,588.436
Income Per Employee -33,902.28
Receivables Turnover 7.777
Total Asset Turnover 1.10

NTRA Liquidity

Current Ratio 3.393
Quick Ratio 3.238
Cash Ratio 2.439

NTRA Profitability

Gross Margin 64.674
Operating Margin -13.27
Pretax Margin -11.625
Net Margin -9.026
Return on Assets -9.926
Return on Equity -14.317
Return on Total Capital -10.803
Return on Invested Capital -13.331

NTRA Capital Structure

Total Debt to Total Equity 12.519
Total Debt to Total Capital 11.126
Total Debt to Total Assets 8.548
Long-Term Debt to Equity 6.918
Long-Term Debt to Total Capital 6.149
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Natera Inc - NTRA

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
820.22M 1.08B 1.70B 2.31B
Sales Growth
+31.13% +31.99% +56.75% +35.90%
Cost of Goods Sold (COGS) incl D&A
456.26M 589.83M 673.75M 814.65M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
30.47M 38.62M 30.97M 43.48M
Depreciation
30.47M 38.62M 30.97M 37.86M
Amortization of Intangibles
- - - 5.62M
-
COGS Growth
+43.29% +29.28% +14.23% +20.91%
Gross Income
363.97M 492.74M 1.02B 1.49B
Gross Income Growth
+18.53% +35.38% +107.65% +45.77%
Gross Profit Margin
+44.37% +45.52% +60.30% +64.67%
2022 2023 2024 2025 5-year trend
SG&A Expense
895.72M 936.31M 1.25B 1.80B
Research & Development
307.13M 318.00M 404.14M 624.11M
Other SG&A
588.59M 618.31M 841.31M 1.17B
SGA Growth
+21.10% +4.53% +33.02% +44.32%
Other Operating Expense
- - - -
-
Unusual Expense
- 9.29M 2.68M 3.90M
EBIT after Unusual Expense
(541.04M) (446.24M) (222.29M) (309.91M)
Non Operating Income/Expense
3.54M 24.35M 43.25M 45.89M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
9.32M 12.64M 10.69M 4.07M
Interest Expense Growth
+12.21% +35.62% -15.45% -61.92%
Gross Interest Expense
9.32M 12.64M 10.69M 4.07M
Interest Capitalized
- - - -
-
Pretax Income
(546.82M) (434.53M) (189.73M) (268.09M)
Pretax Income Growth
-16.07% +20.54% +56.34% -41.30%
Pretax Margin
-66.67% -40.14% -11.18% -11.63%
Income Tax
978.00K 271.00K 695.00K (59.93M)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(547.80M) (434.80M) (190.43M) (208.16M)
Minority Interest Expense
- - - -
-
Net Income
(547.80M) (434.80M) (190.43M) (208.16M)
Net Income Growth
-16.13% +20.63% +56.20% -9.31%
Net Margin Growth
-66.79% -40.16% -11.22% -9.03%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(547.80M) (434.80M) (190.43M) (208.16M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(547.80M) (434.80M) (190.43M) (208.16M)
EPS (Basic)
-5.5666 -3.781 -1.5268 -1.5225
EPS (Basic) Growth
-6.87% +32.08% +59.62% +0.28%
Basic Shares Outstanding
98.41M 115.00M 124.72M 136.72M
EPS (Diluted)
-5.5666 -3.781 -1.5268 -1.5225
EPS (Diluted) Growth
-6.87% +32.08% +59.62% +0.28%
Diluted Shares Outstanding
98.41M 115.00M 124.72M 136.72M
EBITDA
(501.28M) (404.95M) (191.33M) (262.53M)
EBITDA Growth
-18.98% +19.22% +52.75% -37.21%
EBITDA Margin
-61.11% -37.41% -11.27% -11.38%

Snapshot

Average Recommendation BUY Average Target Price 260.762
Number of Ratings 21 Current Quarters Estimate -0.538
FY Report Date 03 / 2026 Current Year's Estimate -1.82
Last Quarter’s Earnings 0.36 Median PE on CY Estimate N/A
Year Ago Earnings -1.52 Next Fiscal Year Estimate -0.61
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 17 19 19
Mean Estimate -0.54 -0.52 -1.82 -0.61
High Estimates -0.27 -0.38 -1.22 1.46
Low Estimate -0.68 -0.65 -2.36 -2.51
Coefficient of Variance -21.17 -15.43 -17.32 -140.33

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 15
OVERWEIGHT 3 4 4
HOLD 2 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Natera Inc - NTRA

Date Name Shares Transaction Value
Mar 5, 2026 Stephen Leonard Chapman CEO AND PRESIDENT; Director 159,435 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $199.17 per share 31,754,668.95
Mar 5, 2026 Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS 152,092 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $198.83 per share 30,240,452.36
Mar 5, 2026 Stephen Leonard Chapman CEO AND PRESIDENT; Director 160,557 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS 150,498 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $200.11 per share 30,116,154.78
Mar 5, 2026 Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 5, 2026 Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER 236,085 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS 150,023 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $200.97 per share 30,150,122.31
Mar 5, 2026 Stephen Leonard Chapman CEO AND PRESIDENT; Director 156,607 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $201.18 per share 31,506,196.26
Mar 5, 2026 John Fesko PRESIDENT, CHIEF BUS. OFFICER 188,132 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Michael Burkes Brophy CHIEF FINANCIAL OFFICER 62,171 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Matthew Rabinowitz EXECUTIVE CHAIRMAN; Director 2,310,772 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Stephen Leonard Chapman CEO AND PRESIDENT; Director 156,972 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $200.24 per share 31,432,073.28
Mar 5, 2026 Jonathan Sheena Director 262,194 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $202.85 per share 53,186,052.90
Mar 5, 2026 Jonathan Sheena Director 262,294 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $201.2 per share 52,773,552.80
Mar 5, 2026 Jonathan Sheena Director 262,394 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $200.42 per share 52,589,005.48
Mar 5, 2026 Jonathan Sheena Director 264,794 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $198.5 per share 52,561,609.00
Mar 5, 2026 Jonathan Sheena Director 265,264 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 5, 2026 Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS 153,023 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $9.59 per share 1,467,490.57
Mar 5, 2026 Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS 147,898 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Oct 31, 2025 John Fesko PRESIDENT, CHIEF BUS. OFFICER 150,699 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $191.46 per share 28,852,830.54

Natera Inc in the News